Dr. Andrei Popov, CEO at Ecrins Therapeutics
Photo credit: Ecrins Therapeutics
Laureate of the 2002 INSERM program “Avenir”, Dr. Andrei Popov launched a research project with a focus on the mechanisms of cell division and bioactive small molecules, both fields relevant to oncology (INSERM and Joseph Fourier University in Grenoble). The discovery of several drug candidates by Drs. Aurélie Juhem and Andrei Popov allowed them, with the support of Prof. François Berger, to create in 2010 Ecrins Therapeutics. The project was awarded in 2009 the grant “Proof-of-concept” by the Lyon Auvergne Rhône-Alpes Cancéropôle and also won the National Innovation Contest for the Creation of Innovative Companies “Emergence” (2009) and “Création-Développement” (2010). The company aims to develop its drug candidates to clinical Proof-of- Concept. The lead drug candidate ET-D5 is a First-in-Class small molecule with an original anti-vascular and anti-proliferative mechanism of action.
– How your background leads you to start your own business?